-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Maintains Outperform on Climb Bio, Raises Price Target to $17

Benzinga·05/08/2026 13:47:45
Listen to the news
Wedbush analyst Laura Chico maintains Climb Bio (NASDAQ:CLYM) with a Outperform and raises the price target from $15 to $17.